Abstract: The present invention concerns methods of reducing bone loss and/or stimulating bone production comprising administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER (SEQ ID NO:1), or variants thereof, to a patient and/or bone cells. The present invention also concerns methods of treatment and/or prophylaxis of musculoskeletal loss and/or damage in a patient, comprising administering an effective amount of the peptide.

Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.

Abstract: The present invention concerns methods of reducing bone loss and/or stimulating bone production comprising administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER (SEQ ID NO:1), or variants thereof, to a patient and/or bone cells. The present invention also concerns methods of treatment and/or prophylaxis of musculoskeletal loss and/or damage in a patient, comprising administering an effective amount of the peptide.

Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.

Abstract: The present invention concerns methods of reducing bone loss and/or stimulating bone production comprising administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER (SEQ ID NO:1), or variants thereof, to a patient and/or bone cells. The present invention also concerns methods of treatment and/or prophylaxis of musculoskeletal loss and/or damage in a patient, comprising administering an effective amount of the peptide.

Abstract: Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N?-SVTEQGAELSNEER-C? (SEQ ID NO: 1) or an analog thereof that inhibits T cell migration. Also provided is the peptide or its analog for use in the methods of treatment and/or prophylaxis of said condition. Also provided is a method for the treatment of Sjogren's syndrome by administration of a peptide comprising N?-SVTEQGAELSNEER-C? to a patient in need thereof.

Abstract: Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N?-SVTEQGAELSNEER-C? (SEQ ID NO: 1) or an analogue thereof that inhibits T cell migration. Also provided is the peptide or its analogue for use in the methods of treatment and/or prophylaxis of said condition. Also provided is a method for the treatment of Sjogren's syndrome by administration of a peptide comprising N?-SVTEQGAELSNEER-C? to a patient in need thereof.

Abstract: Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N?-SVTEQGAELSNEER-C? (SEQ ID NO: 1) or an analog of the peptide that inhibits T cell migration. Also provided is the peptide or its analog for use in the methods of treatment and/or prophylaxis of the condition.

Abstract: CDH15 has been identified as a receptor for a peptide which has an inhibitory effect of the migration of T cells. Agonists of this receptor have applications in the treatment and/or prophylaxis of conditions associated with the migration of T-cells, including T cell auto-reactivity, T cell mediated chronic inflammatory disease and autoimmune disease. The agonist is not PEPITEM or an analogue thereof.

Abstract: A method of determining the likelihood of a patient developing rheumatoid arthritis (RA) is provided, which relies on the use of AdipoR1 and/or AdipoR2 in leukocytes as prognostic markers. The method may comprise determining the expression of A dipoR1 and/or AdipoR2 in leukocytes in a sample from said patient. The method may be used for screening, within a population, one or more patients likely to develop RA.

Abstract: Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N?-SVTEQGAELSNEER-C? {SEQ ID NO: 1) or an analogue thereof that inhibits T cell migration. Also provided is the peptide or its analogue for use in the methods of treatment: and/or prophylaxis of said condition.